PanTheryx, Dr ReddyA's announce supply, licensing agreement

PanTheryx, Inc, a US-based global medical nutrition company, and pharma major Dr.Reddy's Laboratories Ltd., on Wednesday signed a multi-country supply and licensing agreement.

The agreement grants Dr. Reddy's the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention 'DiaResQ' for infectious diarrhoea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select Latin American markets. Dr. Reddy's will market the product in India and Nepal under the Reliqua brand.

DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognized in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.

"This partnership further validates DiaResQ's potential to improve the well-being and quality of life of millions of children and their families globally," said PanTheryx president and CEO Mark A. Braman.

"Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it," said Dr. Reddy's co-chairman and CEO, G.V. Prasad.

Infectious diarrhoea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five. Almost 760,000 of these children under five die every year as a result of this condition. Pediatric infectious diarrhoea kills nearly as many children as HIV/AIDS, malaria and measles combined.